[pubmed] MuSK Myasthenia Gravis Presenting with Bilateral Vocal Cord Abduction Paresis: A Case Report and Literature Rev

[RSS-Bot]

Neurologist. 2021 Sep 7;26(5):175-177. doi: 10.1097/NRL.0000000000000339.

ABSTRACT

INTRODUCTION: Approximately 39% to 49% of patients with previously diagnosed acetylcholine receptor antibody-negative myasthenia gravis have been found to be muscle-specific tyrosine kinase (MuSK) antibody positive. These patients have a presentation that typically includes oculobulbar weakness, poorer response to cholinesterase inhibitors, and higher risk for acute clinical decompensation that necessitates plasma exchange. MuSK patients can require more aggressive maintenance immunosuppression earlier-on to maintain stability, often with rituximab.

CASE REPORT: The authors report the case of a 45-year-old woman who presented with months of worsening hoarseness and exertional dyspnea. Laryngoscopy revealed limited abduction of vocal cords bilaterally as the source of the complaint. Examination revealed ophthalmoparesis and fatigable proximal muscle weakness. She was found to have elevated MuSK antibodies that, along with evidence of neuromuscular junction transmission defect on nerve conduction studies, confirmed the diagnosis of MuSK myasthenia gravis. She experienced no improvement with pyridostigmine and decompensated despite receiving oral steroids, requiring intubation. However, she dramatically improved with plasma exchange and has since been doing well on rituximab therapy.

CONCLUSION: Dysphonia with hoarse quality secondary to vocal cord abduction paresis is a rare presentation of myasthenia gravis, as opposed to the typical flaccid dysarthria seen in bulbar myasthenia and should raise suspicion for MuSK antibody positivity. MuSK myasthenia gravis cases can be more refractory to treatment with cholinesterase inhibitors and are more likely to cause exacerbations and myasthenia crisis. Therefore, early and accurate diagnosis with appropriate antibody testing is imperative to avoid delays in treatment to prevent potentially life-threatening outcomes.

PMID:34491934 | DOI:10.1097/NRL.0000000000000339


Source: https://pubmed.ncbi.nlm.nih.gov/3449193 ... 4&v=2.14.5